Herbalife’s Q2 2024: EBITDA Momentum Offsets FX Headwinds as the Stock Weighs its Levers

Herbalife Ltd. (NYSE: HLF) reports second-quarter 2024 results, with EPS figures, non-GAAP adjustments, and a corporate reshaping that could ripple across the sector.

Snapshot: Q2 2024 results at a glance

Herbalife Ltd., trading as HLF on the NYSE, posted a second-quarter 2024 that looked more like a resilient liverwort than a riotous spring—the kind of quarter where a handful of numbers tell a coherent story even as the macro landscape adds a sour note.

Net sales: $1.3 billion, down 2.5% versus Q2 2023, pressured by 270 basis points of foreign exchange headwinds.
Growth in constant currency: up 0.2% year over year, highlighting pockets of strength outside the FX drag.
Net income: $4.7 million; adjusted net income of $54.8 million.
Adjusted EBITDA: $180.0 million, with a margin up 120 basis points year over year and exceeding guidance.
EPS: GAAP diluted EPS of $0.05; adjusted diluted EPS of $0.54.
Cash flow: Net cash from operating activities of $102.5 million; capital expenditures of about $36 million.
Leverage and liquidity: total leverage ratio reduced to 3.5x at June 30; Credit Agreement EBITDA of $208.0 million.
Capital actions: completed a sale-leaseback of the Torrance, California, office building (sixteen-month leaseback) in July.

On the guidance front, Herbalife revised its full-year 2024 expectations: net sales lower, but adjusted EBITDA guidance raised; capital expenditures reaffirmed. The company also reaffirmed non-GAAP measures and signaled ongoing emphasis on cost discipline and capital allocation.

Analysis: what the numbers imply for Herbalife and peers

The quarter’s standout is adjusted EBITDA, not net income, which serves as the company’s optimist’s compass in a world where FX swings and distributor dynamics can swamp the top line. The $180 million reported figure exceeded management’s guidance, marking a pulse in EBITDA that’s been absent for several quarters. A 120-basis-point margin expansion in the midst of revenue pressure speaks to disciplined cost control and a favorable mix shift into regions where demand remains steadier.

The EPS angle is nuanced: GAAP diluted EPS was $0.05, while adjusted diluted EPS stood at $0.54. The difference reflects the ongoing impact of restructuring programs and debt-related charges that are excluded from the adjusted metric. In practice, this means investors should view the headline EPS with care, recognizing that non-GAAP adjustments can mask the noise—yet the company is explicit that these items are headwinds that don’t reflect ongoing performance.

The FX headwinds—while painful for reported sales—appear to have been managed in a way that the company can point to pockets of growth in Latin America, EMEA, and the Asia-Pacific region on a constant-currency basis. That nuance matters for revenue forecast discussions and for equity holders betting on a path to mid-to-longer-term growth despite a near-term header of currency volatility.

The balance sheet shows leverage improvement, with the total leverage ratio easing to 3.5x as of June 30. A lower leverage backdrop reduces financial risk and gives management room to fund growth initiatives or further bolt-on capital moves without a panic in the debt market. The credit agreement EBITDA figure of $208.0 million anchors the debt capacity against which that leverage ratio is measured.

Management’s commentary underlines a growth thesis anchored in distributor network expansion: “Our Q2 Adjusted EBITDA is the highest it’s been in seven quarters. We remain focused on driving shareholder value as the continued increase in new distributors builds the foundation for sales growth.” That line isn’t just a festive quote; it’s a reminder that the company’s secular growth lever is more organic recruitment and activation of a broader distributor base, rather than an aggressive price or product-laden sprint.

Outlook and guidance: the year ahead in a rewritten map

For the third quarter of 2024, Herbalife provided forward-looking guidance, though the exact figures aren’t spelled out in the filing excerpt. The company also updated its full-year 2024 outlook: revenue (net sales) are expected to be reduced, but adjusted EBITDA guidance was raised, and capital expenditure plans were reaffirmed. In other words, the company is recalibrating expectations to reflect a tighter top-line environment while trying to preserve the profitability machine that already produced a stronger EBITDA print in Q2.

This kind of guidance shift is telling for investors watching the EPS consensus landscape. It signals that management is prioritizing EBITDA quality over hollow top-line bravado, and that the revenue forecast trajectory remains sensitive to FX, pricing, and distributor onboarding.

Takeaways for investors and sector peers

The quarter’s risk-reward setup is nuanced. A disciplined approach to non-GAAP metrics, a clear focus on cash flow generation, and operational leverage through higher-margin segments are positives that peers will watch. For Herbalife, the combination of a contained revenue decline, a robust EBITDA print, and a leverage ratio that has moved lower sets a constructive tone for potential multiple re-rating if FX volatility eases and distributor growth accelerates.

For sector peers, the message—amidst currency-driven volatility and macro headwinds—is that EBITDA discipline and balance-sheet optimization matter more than a sprint to top-line growth alone. The Torrance sale-leaseback signals a continued appetite for asset-light flexibility, a trend likely to echo among other consumer and direct-sell players seeking liquidity without surrendering long-term growth options.

If you’re tracking earnings surprise dynamics, Herbalife’s Q2 release positions EBITDA momentum as the more informative signal versus pure revenue deltas in a quarter still haunted by FX and restructuring costs. The explicit highlight that adjusted EBITDA beat its own guidance, paired with a modest GAAP EPS print, showcases the value of non-GAAP framing in conveying underlying operating momentum—an ongoing theme across consumer-discretionary and direct-selling circles.

Risks and considerations

The narrative relies on non-GAAP adjustments, which require careful interpretation. The mention of restructuring expenses and debt extinguishment headwinds means the GAAP path may look softer than the adjusted path over short horizons. Investors should monitor FX trends, the pace of distributor onboarding, and the durability of the Latin America/EMEA/Asia-Pacific growth drivers that underpinned the underlying margin expansion in the quarter.

And while the company’s EPS trajectory may be restrained by non-cash adjustments, the cash flow resilience—operating cash flow of $102.5 million—offers a buffer for ongoing capital allocation strategies, including the Torrance transaction and potential future optimization moves.

Conclusion: a measured quarter that leans into EBITDA strength

Herbalife’s Q2 2024 results show a company navigating currency headwinds with disciplined cost control, a leaner capital structure, and a plan to sustain profitability even as net sales face a modest decline. The EPS picture remains mixed in GAAP terms, but the adjusted EBITDA beat signals and the near-term guidance tilt suggest a company that prefers to optimize cash generation and leverage up its underlying earnings power rather than ride a quick top-line surge.

For HLF and its peers, the lesson is not a dramatic earnings surprise but a sober reminder that in a world of FX volatility and shifting consumer behavior, the quality of earnings—especially EPS{" "} and revenue forecast clarity—matters more than headline revenue growth. The market will likely trade the stock not on a single quarter’s beat, but on the durability of the post-restructuring EBITDA trajectory and the ability to sustain cash returns to shareholders.

Notes on the non-GAAP disclosure

The press release emphasizes Non-GAAP measures and directs readers to Schedule A for a detailed reconciliation to U.S. GAAP. As with all such disclosures, investors should consider both GAAP and non-GAAP results to form a complete view of the company’s earnings quality and capital efficiency.